Sodium-Glucose Cotransporter-2 inhibitor (SGLT2i) Prescription Rates Amongst Diabetologists for Type 2 Diabetes Patients with Albuminuric Diabetic Kidney Disease:
Prescribing SGLT2i to T2D patients with albuminuric DKD remains suboptimal among diabetologists due to clinical inertia, medication costs, and frailty. Our study underscores actions aimed at improving SGLT2i prescription rates in routine practice.
Authors
- Soontaree Nakasatien (ORCID: https://orcid.org/0000-0002-5032-8296)
- Waralee Chatchomchuan (ORCID: https://orcid.org/0000-0003-0880-6693)
- Thep Himathongkam (ORCID: https://orcid.org/0000-0002-6441-9826)
- Ekgaluck Wanothayaroj
- Siriwan Butadej (ORCID: https://orcid.org/0000-0002-4893-2494)
- Yotsapon Thewjitcharoen (ORCID: https://orcid.org/0000-0002-2317-4041)
- Sirinate Krittiyawong
- Peachaphol Chongvoranond
Institutions
- St Vincent Hospital (US)
Publication Details
- Journal
- Journal of the ASEAN Federation of Endocrine Societies
- Published
- 2025-11-13
- DOI
- https://doi.org/10.15605/jafes.040.02.22
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chulabhorn Royal Academy